Profile

Steven B. Mizel, Ph.D.Wake Forest School of Medicine

Steven B. Mizel, Ph.D.

Professor,


Contact Information

Academic: 336-716-2216 | Department: 336-716-2011

Email: smizel@wakehealth.edu

Education & Training

  • A.B., University of California-Berkeley , 1969
  • Ph.D., Stanford University , 1973
  • Fellowship, Colorado State University, 1974
  • Fellowship, Israel, 1976

Memberships

  • Am Assn Of Advancement Of Scie
  • Am Assn Of Immunologists
  • Assn Of Med Schl Dept Chairmen
Steven B. Mizel, Ph.D.

Steven B. Mizel, Ph.D.

Professor, Microbiology & Immunology
Infectious Diseases
Translational Science Institute

Research Interests

cross(mult/tnslat/inter)discip, drugs/therapeutic agents pharm, immunology/allergy/inflammatio, vaccines

Contact Information

Academic: 336-716-2216 | Department: 336-716-2011

Email: smizel@wakehealth.edu

Recent Publications

Honko AN, Mizel SB, inventors; Wake Forest University Health Sciences, assignee. Use of flagellin in tumor immunotherapy. Canada patent CA 2,589,553. 2014 Feb 18. 2014;():.

Honko AN, Mizel SB, inventors; Wake Forest University Health Sciences, assignee. Use of flagellin in the immunotherapy of Yersinia Pestis. United States patent US 8,198,424. 2012 June 12; Australia patent AU 2005325715. 2012 Jan 19. 2012;():.

Mizel SB, Honko AN, inventors; Wake Forest University Health Sciences, assignee. Use of flagellin in the immunotherapy of yersiniapestis. Japan patent JP 5094407. 2012 Sept 28; European patent office EP 1827489. 2013 May 9. 2012;():.






Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, Lyles DS. Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol. 2010;84(22):12093-98.

Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol. 2010;185(10):5677-5682.

Mizel S, Honko AN, inventors; Wake Forest University Health Sciences, assignee. Use of flagellin in the immunotherapy of yersinia pestis. United States patent US 7,794,731. 2010 Sept 14. 2010;():.

Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO, Hantgan RR, Thomas MJ, Wood J, Bell B. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol. 2009;16(1):21-28.


Bates JT, Uematsu S, Akira S, Mizel SB. Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol. 2009;182(12):7539-7547.


Bates JT, Honko AN, Graff AH, Kock ND, Mizel SB. Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev. 2008;129(5):271-281.

Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, Mizel SB, Parks GD. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J Virol. 2008;82(22):10975-85.

Hickman CL, High KP, Wells JD, Mizel SB. Serum modulation of flagellin-induced human dendritic cell maturation [abstract]. J Immunol. 2006;176(Suppl):S64.

Bates JT, Mizel SB. Flagellin induces a robust innate respiratory immune response in aged mice [abstract]. J Immunol. 2006;176(Suppl):S246-S247.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.